A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether AMG 386, in combination with Sorafenib, is
effective in the treatment of advanced or inoperable Hepatocellular cancer in subjects who
have not received any prior systemic therapy except surgery or locoregional therapy.
Disease status and disease progression will be assessed every 8 weeks. Subjects will remain
on treatment until: progressive disease by RECIST criteria; clinical progression; death or
loss to follow-up; or withdrawal of informed consent.